Company

Glaukos Corporation

Headquarters: San Clemente, CA, United States

Employees: 727

CEO: Mr. Thomas William Burns

NYSE: GKOS +1.44%

Market Cap

$3.86 Billion

USD as of Jan. 1, 2024

Market Cap History

Glaukos Corporation market capitalization over time

Evolution of Glaukos Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Glaukos Corporation

Detailed Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Glaukos Corporation has the following listings and related stock indices.


Stock: NYSE: GKOS wb_incandescent

Stock: FSX: 6GJ wb_incandescent

Details

Headquarters:

229 Avenida Fabricante

San Clemente, CA 92672

United States

Phone: 949 367 9600

Fax: 949 367 9984